These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2307573)

  • 1. Sustained-release dosage forms.
    Geraets D; Burke T
    Iowa Med; 1990 Feb; 80(2):90-4. PubMed ID: 2307573
    [No Abstract]   [Full Text] [Related]  

  • 2. Euphylong. A new sustained-release theophylline pellet formulation for once-daily evening administration.
    Arzneimittelforschung; 1988 Aug; 38(8A):1199-256. PubMed ID: 3190807
    [No Abstract]   [Full Text] [Related]  

  • 3. Steady-state pharmacokinetics of two sustained-release theophylline products during once-daily and twice-daily dosing.
    Armstrong EP; Nako N; Plezia PM; Kramer TH; Jones WN
    Clin Pharm; 1987 Oct; 6(10):800-4. PubMed ID: 3505842
    [No Abstract]   [Full Text] [Related]  

  • 4. Safe and effective use of sustained-release and intravenous theophylline.
    Boggs PB
    Compr Ther; 1982 Mar; 8(3):17-21. PubMed ID: 7067393
    [No Abstract]   [Full Text] [Related]  

  • 5. [Are theophylline determinations useful to the clinician during treatment with a sustained-release form of theophylline?].
    Autret E; Lebranchu Y; Blanchard P; Nsabiyumua F; Breteau M; Grenier B; Jonville AP
    Therapie; 1990; 45(1):19-22. PubMed ID: 2343431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of two long-acting theophylline preparations in daily evening administration].
    Holzer R
    Wien Med Wochenschr; 1993; 143(2):37-42. PubMed ID: 8488685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Manufacture and in vitro characterization of a new fluid theophylline sustained-release form. Sachets with microcapsules for administration in a drinkable sustained-release suspension].
    Weiss G; Klemm FH; Fuchs WS; Stanislaus F; Zema M; Calanchi M
    Arzneimittelforschung; 1998 May; 48(5A):604-12. PubMed ID: 9676353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scleroglucan sustained-release oral preparations. Part I. In vitro experiments.
    Touitou E; Alhaique F; Riccieri FM; Riccioni G; Santucci E
    Drug Des Deliv; 1989 Dec; 5(2):141-8. PubMed ID: 2577984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prescription of Theostat 300 as a single evening dose].
    Germouty J; Bida C; Moreau L
    Rev Pneumol Clin; 1987; 43(5):262-5. PubMed ID: 3324266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of gastroretentive microspheres and sustained-release preparations using theophylline pharmacokinetics.
    Miyazaki Y; Yakou S; Takayama K
    J Pharm Pharmacol; 2008 Jun; 60(6):693-8. PubMed ID: 18498704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative dose study of a theophylline sustained-release tablet formulation after repeated administrations.
    Cova D; Cuglituri G; Rossini L; Bonfardeci G
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):273-5. PubMed ID: 2737795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The design of oral sustained-release theophylline dosing after conversion from intravenous to oral therapy.
    Yamazaki M; Fukutomi O; Kondo N; Kato Z; Nakashima Y; Shinoda S; Agata H; Kondo T; Imaeda N; Orii T
    Int J Clin Pharmacol Ther; 1994 Nov; 32(11):625-31. PubMed ID: 7874380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of oral sustained-release capsules of theophylline.
    Schaaf LJ
    Ann Allergy; 1979 Oct; 43(4):259-60. PubMed ID: 555605
    [No Abstract]   [Full Text] [Related]  

  • 14. Determination of intraluminal theophylline concentrations after oral intake of an immediate- and a slow-release dosage form.
    Brouwers J; Ingels F; Tack J; Augustijns P
    J Pharm Pharmacol; 2005 Aug; 57(8):987-96. PubMed ID: 16102254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of long-term oral administration of a sustained release theophylline preparation in children with chronic asthma.
    Cantani A; Businco E; Businco L; Solano A; Calabretta C
    Allergol Immunopathol (Madr); 1983; 11(1):11-4. PubMed ID: 6858803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of a new sustained-release formulation of theophylline sodium glycerinate in healthy subjects with a new asymmetric dosage regimen.
    Wang P; Qi M; Zhong D; Fang L
    Biomed Chromatogr; 2003 Jan; 17(1):58-61. PubMed ID: 12583008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of 2 theophylline delayed-action preparations of different galenic forms].
    Hirsch H
    Wien Med Wochenschr; 1983 Aug; 133(15-16):403-8. PubMed ID: 6636797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theophylline molecularly imprinted polymer dissociation kinetics: a novel sustained release drug dosage mechanism.
    Norell MC; Andersson HS; Nicholls IA
    J Mol Recognit; 1998; 11(1-6):98-102. PubMed ID: 10076816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theophylline controlled-release formulations: in vivo-in vitro correlations.
    Yu Z; Schwartz JB; Sugita ET
    Biopharm Drug Dispos; 1996 Apr; 17(3):259-72. PubMed ID: 8983400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
    Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
    Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.